Interaction analysis of hub genes. by Jiyong Zhang (2498740)

Subjects:

The p21 ELISA assay was used to assess the effects of MBC-005 on tumor cell expression of p21. by Bryan S. Margulies (21492667)

Subjects:

Flow diagram of participants selection. by Wei Huang (36889)

Subjects:

Minimal data set. by Wei Huang (36889)

Subjects:

Weighted comparison of baseline characteristics. by Wei Huang (36889)

Subjects:

E (soil aggregate stability energy) is the amount of energy required when 99% of the soil is disrupted, Ecrit (soil critical stabilization energy) is the energy required when the i... by Xiaoxu Zhu (11764430)

Subjects:

Cox proportional hazard ratios. by Bryan S. Margulies (21492667)

Subjects:

Bioluminescent Doubling Time. by Bryan S. Margulies (21492667)

Subjects:

Study Design. by Bryan S. Margulies (21492667)

Subjects:

Table 2_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx by Jinyu He (19774641)

“…However, MRA therapy was associated with an increased risk of renal dysfunction, including hyperkalemia (RR = 2.086, 95% CI: 1.872–2.325, p < 0.001; I² = 0.0%), elevated serum creatinine (RR = 1.512, 95% CI: 1.252–1.825, p < 0.001; I² = 0.0%), decreased eGFR (WMD = −5.223, 95% CI: −7.380 to −3.066, p < 0.001; I² = 0.0%), and potentially increased incidence of composite renal outcomes.…”

Table 1_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx by Jinyu He (19774641)

“…However, MRA therapy was associated with an increased risk of renal dysfunction, including hyperkalemia (RR = 2.086, 95% CI: 1.872–2.325, p < 0.001; I² = 0.0%), elevated serum creatinine (RR = 1.512, 95% CI: 1.252–1.825, p < 0.001; I² = 0.0%), decreased eGFR (WMD = −5.223, 95% CI: −7.380 to −3.066, p < 0.001; I² = 0.0%), and potentially increased incidence of composite renal outcomes.…”

Table 3_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx by Jinyu He (19774641)

“…However, MRA therapy was associated with an increased risk of renal dysfunction, including hyperkalemia (RR = 2.086, 95% CI: 1.872–2.325, p < 0.001; I² = 0.0%), elevated serum creatinine (RR = 1.512, 95% CI: 1.252–1.825, p < 0.001; I² = 0.0%), decreased eGFR (WMD = −5.223, 95% CI: −7.380 to −3.066, p < 0.001; I² = 0.0%), and potentially increased incidence of composite renal outcomes.…”

Data Sheet 1_Ribosomal protein L9 is a potential therapeutic target for B-ALL through the activation of the p53 signaling pathway.docx by Xinxin Li (281237)

“…Enforced RPL9 knockdown (KD) led to decreased proliferation and increased apoptosis in B-ALL cells compared to the control group. …”

Disruption of <i>shk-1</i> increases susceptibility to bacterial pathogens. by Longjun Pu (20685717)

All data extracted. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Changes in the eGFRs and serum potassium levels compared with values at the end of 1 month of treatment in all patients over time. by Jia Song (495396)

Means, standard deviations, and inferential statistics for the outcomes in the three conditions tested. by Robert Trybulski (10998702)

Subjects:

Leg Stabilization During Measurements arterial occlusion pressure. by Robert Trybulski (10998702)

Subjects:

Example of LDF recording during post-occlusive reactive hyperemia (PORH). by Robert Trybulski (10998702)

Subjects:

CONSORT 2025 Flow Diagram [70]. by Robert Trybulski (10998702)

Subjects: